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ORIGINAL ARTICLE – HEALTHCARE POLICY AND OUTCOMES
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ABSTRACT
Background. Hyperparathyroidism (HPT), both sec-
ondary and tertiary, is common in patients with end-stage
renal disease, and is associated with severe bone disorders,
cardiovascular complications, and increased mortality.
Since the introduction of calcimimetics in 2004, treatment
of HPT has shifted from surgery to predominantly medical
therapy.
Objective. The aim of this study was to evaluate the
impact of this change of management on the HPT patient
population before undergoing (sub-)total parathyroidec-
tomy (PTx).
Methods. Overall, 119 patients with secondary or tertiary
HPT undergoing PTx were included in a retrospective,
single-center cohort. Group A, who underwent PTx before
January 2005, was compared with group B, who underwent
PTx after January 2005. Patient characteristics, time
interval between HPT diagnosis and PTx, and postopera-
tive complications were compared.
Results. Group A comprised 70 (58.8 %) patients and
group B comprised 49 (41.2 %) patients. The median
interval between HPT diagnosis and PTx was 27 (in-
terquartile range [IQR] 12.5–48.0) and 49 (IQR 21.0–75.0)
months for group A and B, respectively (p = 0.007).
Baseline characteristics were similar among both groups.
The median preoperative serum parathyroid hormone
(PTH) level was 936 pg/mL (IQR 600–1273) for group A
versus 1091 pg/mL (IQR 482–1373) for group B
(p = 0.38). PTx resulted in a dramatic PTH reduction (less
than twofold the upper limit: A, 80.0 %; B, 85.4 %), and
postoperative complication rates were low in both groups
(A: 7.8 %; B: 10.2 %) [p = 0.66].
Conclusions. The introduction of calcimimetics in 2004 is
associated with a significant 2-year delay of surgery with
continuously elevated preoperative PTH levels, while
parathyroid surgery, even in a fragile population, is con-
sidered a safe and effective procedure.
Hyperparathyroidism (HPT) is a common complication
in patients with end-stage renal disease (ESRD).1,2 In
chronic kidney disease (CKD), calcium and phosphate
homeostasis are progressively deregulated, resulting in
CKD-related mineral and bone disorders (CKD-MBD),
commonly accompanied by secondary HPT.3,4 Tertiary
HPT develops when hyperplastic parathyroid glands no
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longer respond to the plasma calcium concentration and
function autonomously, which is clinically most evident
when HPT does not resolve after successful kidney trans-
plantation (KTx).5,6 Both secondary and tertiary HPT are
associated with cardiovascular complications and increased
mortality.7–10
More than a decade ago, the main treatment options for
HPT consisted of calcium-containing phosphate binders,
vitamin D sterols and (sub-)total parathyroidectomy
(PTx).11 More recently, recommended strategies include
the use of (primarily) non-calcium-containing phosphate
binders, vitamin D analogs, or a combination of these to
decrease parathyroid hormone (PTH) levels.12 PTx is cur-
rently only recommended in patients with severe HPT who
fail to respond to medical treatment.12 Since its introduc-
tion in 2004, the calcimimetic agent cinacalcet has become
a common first-line therapy for HPT patients insufficiently
responsive to vitamin D and phosphate binders. Despite the
lack of randomized studies that directly compare cinacalcet
with PTx, the introduction of cinacalcet seems to have led
to a change in treatment strategy and, consequently, PTx is
less often performed.13 Despite this policy change, several
questions have been raised about the efficacy, side effect
profile, and costs of cinacalcet.14,15 Moreover, studies
evaluating the effect of cinacalcet on lowering PTH levels
show contradictory results.7,14,16 A recent Cochrane
review, which was strongly driven by the primary results
from the EVOLVE trial, concluded that there is no clear
evidence that cinacalcet reduces the risk of death or major
cardiovascular events.16,17 Consequently, cinacalcet is no
longer subsidized by the Australian Government.18 It is
unclear how the introduction of cinacalcet affected the
secondary and tertiary HPT patient population ultimately
requiring PTx. To address this, we performed a retro-
spective, single-center observational study to compare PTx
patient characteristics, time from diagnosis to surgery, and




The study population of this retrospective, single-center
study consisted of all ESRD patients with secondary or ter-
tiary HPT who underwent PTx and were aged 18 years and
older at the time of surgery at the University Medical Center
Groningen (UMCG), The Netherlands, between 1991 and
2015. Patients were excluded if they had (para-)thyroid
malignancy in their medical history and/or previous surgery
in the neck area. Data of the included patients were extracted
from the hospital’s electronic patient record system.
This study was approved by the local Medical Ethical
Committee (METc 2015/339), and patient data were pro-
cessed and electronically stored according to the
declaration of Helsinki Ethical principles for medical
research involving human subjects.
Study Design, Primary and Secondary Endpoints
Patients were divided into two groups according to date of
surgery: before (group A) or after (group B) January 2005, as
cinacalcet was introduced in The Netherlands in 2005.
The primary outcome measure was time from HPT
diagnosis to PTx. Date of HPT diagnosis was defined as the
moment vitamin D supplements were first prescribed to
suppress PTH overproduction. Furthermore, we compared
patient characteristics prior to surgery, including age, sex,
American Society of Anesthesiologists (ASA) physical sta-
tus classification, body mass index (BMI), history of
diabetes mellitus (DM) according to the American Diabetes
Association (ADA) 2010 criteria,19 time on dialysis, type of
PTx, use of vitamin D analogs, phosphate binders and
cinacalcet, and a history of KTx. Furthermore, laboratory
values (calcium, phosphate, albumin, alkaline phosphatase
and PTH) and 30-day postoperative complications were
recorded. The serum calcium level was adjusted for albumin
according to the following formula: adjusted total calcium
(mmol/L) = measured calcium (mmol/L) ? (0.025 * (40 –
[albumin (g/L)]). Reference values were 2.20–2.60 mmol/L.
From 1991 until 2006, PTH analysis was performed using
the PTH-intact assay from Nichols Institute Diagnostics
(San Juan Capistrano, CA, USA). In this period, several
assays have been deployed in our patients, using the same
antibodies with different detection methods (radioim-
munoassay and chemiluminescent immunoassays). Since
February 2006, PTH has been analyzed using PTH-intact
assays using the Immulite 2500 (Siemens Healthcare Diag-
nostics, Deerfield, IL, USA) and the Cobas e601
immunology analyzer (Roche Diagnostics, Mannheim,
Germany). In-house comparison of consecutive PTH assays
showed only significant deviation between the Nichols
Advantage ILMA and the Siemens Immulite 2500. To
compare data before and after the method conversion, the
data before 2006 were recalculated using the following
conversion factor: Immulite (pmol/L) = 1.27 9 Advantage
(pmol/L) ? 0.5.20–22 Reference values for PTH were 16–
87 pg/mL or 1.8–9.6 pmol/L.
Persistent postoperative hypocalcemia was defined as
the need for calcium supplements 6 months after PTx.
Information about weight of the removed parathyroid
glands was extracted from pathology reports; the weight of
the largest removed parathyroid gland was used for com-
parative analyses.
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Statistical Analysis
Descriptive tests were used to express continuous vari-
ables as mean ± standard deviation (SD) or median with
interquartile range (IQR), and categorical variables were
described as count (n) and percentage (%). Patient char-
acteristics were compared using the independent sample t-
test or Mann–Whitney U-test for continuous variables, and
differences between nominal variables were determined
using the Pearson Chi-square test. Distribution was asses-
sed using the Shapiro–Wilk normality test. p-Values\0.05
were considered statistically significant. Statistical analysis
was performed using SPSS Statistics version 22.0 (IBM
Corporation, Armonk, NY, USA.)
RESULTS
Study Population
Between 1991 and 2015, a total of 484 PTxs were
performed in our center. After applying the aforementioned
inclusion and exclusion criteria, a total of 119 (24.6 %)
patients were included in the study (Fig. 1).
Patient Characteristics
Patient characteristics at PTx are listed in Table 1.
Seventy patients (58.8 %) underwent PTx before the
introduction of cinacalcet (group A) and 49 (41.2 %)
patients underwent PTx after the introduction of cinacalcet
(group B). Median age of all patients was 53.0 years (IQR
40–60), 62.2 % were women, and 82.4 % of all patients
were classified as ASA III or higher. At the time of PTx,
77.9 % of all patients received vitamin D analogs and/or
phosphate binders (63.7 % received vitamin D supple-
ments and 61.9 % received phosphate binders). After
January 2005, 88.9 % of the prescribed phosphate binders
were non-calcium-containing versus 41.2 % before January
2005 (p\ 0.001). In group B, 30 patients (61.2 %) were
using cinacalcet at the time of PTx. There was no signifi-
cant difference in the number of parathyroid surgeries per
year before versus after 2005 [median (IQR) 4.0 (2.0–9.0)
vs. 4.0 (2.0–5.0); p = 0.65). The median interval between
HPT diagnosis and PTx was 27 months (12–48) for group
A and 49 months (21.0–75.0) for group B (p = 0.007). A
diagram illustrating the delay from diagnosis of HPT until
PTx after 2005 is presented in Fig. 2.
All PTx from 1991-
2015 in the UMCG 
N = 484
All PTx with the 
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Patients not using 
cinacalcet
N = 19
FIG. 1 Cohort patient selection
process. PTx parathyroidectomy,
UMCG University Medical Center
Groningen, ESRD end-stage renal
disease, HPT hyperparathyroidism
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Biochemistry
Preoperative laboratory values are listed in Table 2.
PTH levels were strongly elevated in both groups [median
(IQR) 936 pg/mL (600–1273) and 1091 pg/mL (482–1373)
for groups A and B respectively; p = 0.38). Mean
corrected calcium level was 2.60 ± 0.34 mmol/L, and was
significantly different between the two groups (p = 0.008)
Median preoperative, intraoperative and postoperative
PTH levels are shown in Fig. 3. PTH levels decreased
significantly after PTx: at 3 months after PTx the median
PTH reduction from baseline was 96.0 % (84.6–99.1).









24.5 (12.5 – 46.5) months
44.0 (17.0 – 69.0) months




Before the introduction of cinacalcet
After the introduction of cinacalcet
FIG. 2 Timeline from diagnosis of hyperparathyroidism until parathyroidectomy. HPT hyperparathyroidism
TABLE 1 Patient characteristics before parathyroidectomy
Characteristic Overall [N = 119] Group A—before the
introduction of
cinacalcet [N = 70]
Group B—after the
introduction of
cinacalcet [N = 49]
p-Value
Age at surgery, years 53.0 (40.0–60.0) 52.5 (40.8–60.0) 54.0 (38.5–59.5) 0.81
Sex, female 74 (62.2) 47 (67.1) 27 (55.1) 0.18
BMI, kg/m2 24.3 (21.4–27.1) 23.4 (20.7–25.8) 25.3 (23.3–27.3) 0.05
History of diabetes 0.21
Type I 3 (2.5) 1 (1.4) 2 (4.1)
Type II 11 (9.2) 8 (11.4) 3 (6.1)
Steroid-induced diabetes 2 (1.7) 0 (0) 2 (4.1)
ASA classification 0.12
II 21 (17.6) 9 (12.9) 12 (24.5)
III 97 (81.5) 61 (87.1) 36 (73.5)
IV 1 (0.8) 0 (0) 1 (2.0)
History of KTx 21 (17.9) 11 (15.7) 10 (21.3) 0.66
Receiving dialysis 90 (76.3) 57 (81.4) 33 (68.8) 0.11
Duration of dialysis, months 46.0 (24.0–76.0) 46.0 (28.0–78.0) 48.5 (21.5–76.0) 0.67
Use of vitamin D analogs 72 (63.7) 38 (59.4) 34 (69.4) 0.27
Use of phosphate binders 70 (61.9) 34 (53.1) 36 (73.5) 0.03
Non-calcium-containing 46 (65.7) 14 (41.2) 32 (88.9) \0.001
Use of cinacalcet 30.0 (25.2) 0 (0.0) 30 (61.2) \0.001
Time interval from HPT diagnosis to PTx,
months
33.5 (16.8–56.3) 27.0 (12.5–48.0) 49.0 (21.0–75.0) 0.007
Data are expressed as median (interquartile range) or n (%)
BMI body mass index, ASA American Society of Anaesthesiologists, KTx kidney transplantation, HPT hyperparathyroidism, PTx
parathyroidectomy
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Overall, at 3 months after PTx, 82.4 % of all patients had
PTH levels below 162 pg/mL (two times the upper refer-
ence limit, acceptable according to the Kidney Disease:
Improving Global Outcomes [KDIGO] guidelines).
Patients in groups A and B had postoperative PTH levels of
45.0 pg/mL (9.6–152.3) and 20.5 pg/mL (2.5–94.6),
respectively. Postoperative PTH levels were not signifi-
cantly different (p = 0.079). Although PTH levels slightly
increased at 5 years after PTx [37.3 pg/mL (6.8–107.7) at 3
months postoperatively vs. 80.5 pg/mL (19.7–193.2) at 5
years postoperatively; p = 0.04], 68.2 % of all patients still
had PTH levels below 162 pg/mL.
Parathyroid Gland Weight
Median weight of the largest resected parathyroid gland
was 1.16 g (0.70–1.86). No significant difference in
parathyroid gland weight was observed between groups A
and B [median (IQR) 1.11 g (0.63–1.82) vs. 1.28 g (0.72–
1.90), respectively; p = 0.51).
Re-Exploration Rate
Six patients (5.0 %) required re-exploration. In four
cases, persistent HPT was the indication for re-exploration,
while the two remaining patients had recurrent HPT. Five
of six patients who underwent re-exploration underwent
subtotal PTx, and one patient underwent total PTx with
autotransplantation. In study group A, re-exploration was
required in five (7.1 %) cases, while one (2.0 %) patient in
group B underwent reoperation. The difference in re-ex-
ploration rate between the two groups did not reach
statistical significance (p = 0.21). Median time from initial
PTx to re-exploration was 23.5 months (4–68).
Postoperative Complications
Postoperative complications are listed in Table 3. In all
patients, the number of complications, including mortality,
recurrent laryngeal nerve damage, surgical site problems
(SSP), pneumonia, and intensive care unit (ICU) admission
was 10 in total (8.8 %). Only one (0.8 %) patient presented
with postoperative wound bleeding that required reopera-
tion. Other wound problems were minimal and comprised
minute bleeding or minor infection requiring antibiotics.
No significant difference in the number of complications
was observed between the two groups (p = 0.66).
DISCUSSION
This single-center, retrospective study documents a
significant 22-month delay from diagnosis to (sub-)total
PTx in patients with HPT since the introduction of the
calcimimetic agent cinacalcet in 2005. Moreover, we
observed that, even after the introduction of cinacalcet,
median preoperative PTH levels have remained unchanged.






































FIG. 3 Median preoperative, intraoperative and postoperative PTH
levels of 119 patients undergoing parathyroidectomy. PTH parathy-
roid hormone
TABLE 2 Preoperative laboratory variables
Overall [N = 119] Group A—before the introduction
of cinacalcet [N = 70]
Group B—after the
introduction of
cinacalcet [N = 49]
p-Value
PTH, pg/mL 963.6 (527.3–1300.0) 936.4 (600.0–1272.7) 1091.0 [482.2-1372.8] 0.38
Corrected calcium, mmol/L 2.60 ± 0.34 2.67 ± 0.36 2.50 ± 0.28 0.008
Phosphorus, mmol/L 1.59 ± 0.58 1.67 ± 0.56 1.49 ± 0.60 0.09
Alkaline phosphatase, U/L 147.5 (99.25–203.75) 150.5 (100.5–226.0) 137.0 [94.0-194.5] 0.48
Calcium-phosphorus product, mmol2/L2 4.06 (2.98–5.19) 4.34 (3.27–5.82) 3.47 (2.55–4.74) 0.01
Data are expressed as mean ± SD or median (interquartile range)
PTH parathyroid hormone
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treatment of patients with HPT and the consequently pro-
longed exposure to high PTH levels. To our knowledge,
this is the first study documenting the difference in time
interval between HPT diagnosis and parathyroid surgery
since cinacalcet became available.
Several reasons may underlie the 22-month referral
delay. First, in the past decade, there has been an increasing
interest for the medical treatment of HPT, particularly with
cinacalcet.23 The availability of cinacalcet seems to have
contributed to a strategy change intending to delay surgery
as long as medically possible, and preferably until KTx,
which might result in resolution of HPT.5 Indeed, several
studies have aimed to reduce the incidence of PTx.13,16,24
However, whether delaying surgery with long-term medi-
cal therapy is truly beneficial for the individual patient is
unknown. While waiting for KTx, HPT often becomes
refractory, eventually leading to an unavoidable PTx.23
Eventually, approximately 30 % of transplanted patients
have ongoing (tertiary) HPT.6 When calcium-phosphate
homeostasis does not normalize after KTx, medical treat-
ment often delays definite surgical intervention, as Lou
et al. concluded that PTx is underused in patients with
tertiary HPT.5,6 Therefore, we need predictive factors for
developing refractory or tertiary HPT to determine in
advance which patients will eventually need PTx after
transplantation. In The Netherlands, the Dutch Hyper-
parathyroid Study Group (DHSG), a multicenter initiative,
is currently trying to answer these questions in larger ret-
rospective patient data sets.25 A second reason for the
observed referral delay may be that standardized and
specific indications for referral for surgery are not avail-
able.5,23 The overall change in guidelines of HPT
management might be another explanation for the late
referral. The 2003 Kidney Disease Outcomes Quality Ini-
tiative (K/DOQI) guidelines recommended maintaining
PTH values below 300 pg/mL (three to five times the upper
limit), whereas the 2009 KDIGO guidelines recommended
PTH levels between two and nine times the upper limit (up
to 746 pg/mL; grade 2C recommendation) 11,12; however,
little evidence is available to support these (changes in)
guidelines. Lastly, group B received predominantly non-
calcium-containing phosphate binders as opposed to group
A patients, who mainly received calcium-containing
phosphate binders. This prescription change might have
also led to a referral delay as patients using calcium-con-
taining medication might be referred in an earlier stage
because of high serum calcium levels.
This study was not designed to conclude whether
patients would benefit from earlier surgery; however, with
the persistence of long-term elevated PTH levels in ESRD
patients, several problems may arise. Tentori et al. found a
positive correlation between elevated PTH levels and car-
diovascular, and all-cause mortality and increased
cardiovascular hospitalization.2 Although data on the
effects of long-term elevated PTH levels on kidney (graft)
function are limited, a large post hoc analysis showed a
significant association between tertiary HPT and adverse
graft outcome after KTx.26 In addition, long-term conser-
vative treatment using vitamin D derivatives, phosphate
binders and calcimimetics entails high costs.17,27 A cost
utility analysis showed that PTx is less expensive and more
cost effective at 7.25 months in comparison to cinacalcet-
based medical therapy.15 Finally, the EVOLVE trial
revealed a high incidence of adverse effects accompanying
cinacalcet use (adverse effects such as vomiting and nausea
were reported at 45.9 % in the cinacalcet group vs. 18.9 %
in placebo group), often leading to discontinuation of the
drug.16
Even after a 22-month delay in this very fragile popu-
lation (ASA III or even IV), parathyroid surgery led to low
complication rates and an effective decrease in PTH levels.
It could be that the potential adverse effects of the delayed
referral are balanced by the improved quality of parathy-
roid surgery with the use of less invasive surgical
procedures, concentration of care in specialized centers,
heat sealing devices, and improved imaging for preopera-
tive localization.28,29
TABLE 3 Postoperative complications
Overall [N = 119] Group A—before the
introduction of
cinacalcet [N = 70]
Group B—after the
introduction of
cinacalcet [N = 49]
p-Value
Mortality 1 (0.8) 0 (0.0) 1 (2.0) 0.23
Recurrent laryngeal nerve damage 2 (1.8) 0 (0.0) 2 (4.1) 0.10
Surgical site problems 4 (3.5) 3 (4.7) 1 (2.0) 0.45
Pneumonia 2 (1.8) 2 (3.1) 0 (0.0) 0.21
ICU admission 1 (0.8) 0 (0.0) 1 (2.0) 0.25
Calcium supplements 6 months postoperatively 45 (39.8) 27 (42.2) 18 (36.7) 0.56
Data are expressed as n (%)
ICU intensive care unit
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Our results regarding safety are at variance with a
nationwide US study showing much higher complication
rates, supporting the need to concentrate PTx procedures in
higher-volume, specialized centers.30 Moreover, our results
are in line with other previous studies demonstrating much
lower complication rates, including mortality, recurrent
laryngeal nerve damage, SSP, and ICU admission occur-
ring at\10 %.5,31–34 Although not significant, there were
less reoperations in the group after the introduction of
cinacalcet. With our current data, we were not able to
conclude whether there is a relationship between the use of
cinacalcet and the need for re-explorations.
This study has certain limitations that need to be
addressed. First, because of its retrospective nature, our
data may be biased by variations in the recording methods
used in our electronic patient record systems, and patients
lost to follow-up. Second, our results may have limited
generalizability as they were from a single-center study.
Our study was not designed to compare PTx with
cinacalcet. Preparations for a large, multicenter, random-
ized control trial comparing PTx and cinacalcet with long-
term follow-up to define the treatment of choice in patients
with chronic renal failure are currently underway in The
Netherlands (RHINO trial).
CONCLUSIONS
The introduction of cinacalcet is associated with a 22-
month delay of surgical treatment of HPT. Since the
introduction of calcimimetics, we have not recorded lower
preoperative PTH levels. On the other hand, parathyroid
surgery, even in a fragile population, is considered both an
effective and safe procedure.
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